ONKOTRONE

This brand name is authorized in Australia, Estonia, Lithuania, Malta, New Zealand, Romania, United Kingdom

Active ingredients

The drug ONKOTRONE contains one active pharmaceutical ingredient (API):

1 Mitoxantrone UNII BZ114NVM5P - MITOXANTRONE

Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. Read about Mitoxantrone

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ONKOTRONE Concentrate for solution for infusion	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01DB07	Mitoxantrone	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01D Cytotoxic antibiotics and related substances → L01DB Anthracyclines and related substances
Discover more medicines within L01DB07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 4514N, 7252Q
Country: EE	Ravimiamet	Identifier(s): 1011621, 1069950, 1069961, 1069972
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 44661, 44676
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1007455, 1067038
Country: MT	Medicines Authority	Identifier(s): AA1277/04401
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 9035
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W42735002, W42735003, W42735004, W42735005